KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Carcinoma, Non-Small-Cell Lung
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 450 (planned)
- Started
- Dec 19, 2019
- Main results expected
- Feb 13, 2032
- Fully finished
- Oct 13, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Measured over: Up to approximately 24 months
Part B: Number of Participants Who Experience One or More Adverse Events (AEs)
Measured over: Up to approximately 27 months
Part B: Number of Participants Who Discontinue Study Intervention Due to an Adverse Event (AE)
Measured over: Up to approximately 24 months
Part B: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)
Measured over: Up to approximately 3 Weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04165070 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC